Dainippon Sumitomo Allergy Drug Enters Phase I Trials
This article was originally published in PharmAsia News
Executive Summary
Dainippon Sumitomo Pharma announced that an allergic disorder agent that was jointly developed with AstraZeneca has entered Phase I trials. An immune response modifier with agonistic activity against toll-like receptor 7, the drug candidate will re-balance Th1/Th2 cells that were found shifted in allergy patients. The company hopes the compound will provide long term remission for patients with bronchial asthma and allergic rhinitis. Under the collaboration agreement, DSP will retain development and market rights in Japan, China, South Korea, and option rights to co-promote in the U.S. and major European countries. AstraZeneca will pay running royalties based on sales after the launch of the products. (Click here for more - Japanese language